Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.

2.50
Hdl Handle:
http://hdl.handle.net/11287/594618
Title:
Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
Authors:
Gray, Richard; Ives, Natalie; Rick, Caroline; Patel, Smitaa; Gray, Alastair; Jenkinson, Crispin; McIntosh, Emma; Wheatley, Keith; Williams, Adrian; Clarke, Carl E; PD MED Collaborative Group incl:; Fenwick, Gill M; Gormley, Kevin (Joe); Gutowski, Nicholas J.; Harrower, Timothy; Hemsley, Anthony; Honan, Will; James, Martin; Malone, Timothy; Pearce, Vaughan R; Sheridan, Ray; Soper, Claire; Zeman, Adam
Abstract:
Whether initial treatment for Parkinson's disease should consist of levodopa, dopamine agonists, or monoamine oxidase type B inhibitors (MAOBI) is uncertain. We aimed to establish which of these three classes of drug, as initial treatment, provides the most effective long-term control of symptoms and best quality of life for people with early Parkinson's disease.
Citation:
Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. 2014, 384 (9949):1196-205 Lancet
Publisher:
Elsevier
Journal:
Lancet (London, England)
Issue Date:
27-Sep-2014
URI:
http://hdl.handle.net/11287/594618
DOI:
10.1016/S0140-6736(14)60683-8
PubMed ID:
24928805
Additional Links:
http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(14)60683-8
Note:
RD&E staff can access the full-text of this article by clicking on the 'Additional Link' above and logging in with NHS OpenAthens if prompted.
Type:
Journal Article; Comparative Study; Multicenter Study; Randomized Controlled Trial
Language:
en
Description:
The RD&E was one of the largest recruiting sites in this study. PD MED Collaborative Group members from the RD&E were: G Fenwick, K Gormley, N Gutowski, S Harris, T Harrower, A Hemsley, W Honan, M James, O Jeffreys, T Malone*, V Pearce, R Sheridan, C Soper, J Sword, A Zeman
ISSN:
1474-547X
Appears in Collections:
Healthcare for Older People; Neurology; 2014 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorGray, Richarden
dc.contributor.authorIves, Natalieen
dc.contributor.authorRick, Carolineen
dc.contributor.authorPatel, Smitaaen
dc.contributor.authorGray, Alastairen
dc.contributor.authorJenkinson, Crispinen
dc.contributor.authorMcIntosh, Emmaen
dc.contributor.authorWheatley, Keithen
dc.contributor.authorWilliams, Adrianen
dc.contributor.authorClarke, Carl Een
dc.contributor.authorPD MED Collaborative Group incl:en
dc.contributor.authorFenwick, Gill Men
dc.contributor.authorGormley, Kevin (Joe)en
dc.contributor.authorGutowski, Nicholas J.en
dc.contributor.authorHarrower, Timothyen
dc.contributor.authorHemsley, Anthonyen
dc.contributor.authorHonan, Willen
dc.contributor.authorJames, Martinen
dc.contributor.authorMalone, Timothyen
dc.contributor.authorPearce, Vaughan Ren
dc.contributor.authorSheridan, Rayen
dc.contributor.authorSoper, Claireen
dc.contributor.authorZeman, Adamen
dc.date.accessioned2016-01-22T14:47:04Zen
dc.date.available2016-01-22T14:47:04Zen
dc.date.issued2014-09-27en
dc.identifier.citationLong-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. 2014, 384 (9949):1196-205 Lanceten
dc.identifier.issn1474-547Xen
dc.identifier.pmid24928805en
dc.identifier.doi10.1016/S0140-6736(14)60683-8en
dc.identifier.urihttp://hdl.handle.net/11287/594618en
dc.descriptionThe RD&E was one of the largest recruiting sites in this study. PD MED Collaborative Group members from the RD&E were: G Fenwick, K Gormley, N Gutowski, S Harris, T Harrower, A Hemsley, W Honan, M James, O Jeffreys, T Malone*, V Pearce, R Sheridan, C Soper, J Sword, A Zemanen
dc.description.abstractWhether initial treatment for Parkinson's disease should consist of levodopa, dopamine agonists, or monoamine oxidase type B inhibitors (MAOBI) is uncertain. We aimed to establish which of these three classes of drug, as initial treatment, provides the most effective long-term control of symptoms and best quality of life for people with early Parkinson's disease.en
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urlhttp://linkinghub.elsevier.com/retrieve/pii/S0140-6736(14)60683-8en
dc.subjectWessex Classification Subject Headings::Neurology::Diseases & disorders of the nervous system (e.g. Parkinson's)en
dc.titleLong-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.en
dc.typeJournal Articleen
dc.typeComparative Studyen
dc.typeMulticenter Studyen
dc.typeRandomized Controlled Trialen
dc.identifier.journalLancet (London, England)en
dc.description.noteRD&E staff can access the full-text of this article by clicking on the 'Additional Link' above and logging in with NHS OpenAthens if prompted.en
dc.description.fundingPD MED was supported by funding from the UK National Institute for Health Research Health Technology Assessment Programme (project number 98/03/02). The University of Birmingham Clinical Trials Unit also received support from the UK Department of Health.en
dc.type.versionPublisheden

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.